» Articles » PMID: 21461351

Therapeutic Implications of Targeting AKT Signaling in Melanoma

Overview
Journal Enzyme Res
Publisher Hindawi
Date 2011 Apr 5
PMID 21461351
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Identification of key enzymes regulating melanoma progression and drug resistance has the potential to lead to the development of novel, more effective targeted agents for inhibiting this deadly form of skin cancer. The Akt3, also known as protein kinase B gamma, pathway enzymes regulate diverse cellular processes including proliferation, survival, and invasion thereby promoting the development of melanoma. Accumulating preclinical evidence demonstrates that therapeutic agents targeting these kinases alone or in combination with other pathway members could be effective for the long-term treatment of advanced-stage disease. However, currently, no selective and effective therapeutic agent targeting these kinases has been identified for clinical use. This paper provides an overview of the key enzymes of the PI3K pathway with emphasis placed on Akt3 and the negative regulator of this kinase called PTEN (phosphatase and tensin homolog deleted on chromosome 10). Mechanisms regulating these enzymes, their substrates and therapeutic implications of targeting these proteins to treat melanoma are also discussed. Finally, key issues that remain to be answered and future directions for interested researchers pertaining to this signaling cascade are highlighted.

Citing Articles

Physiological functions of calcium signaling via Orai1 in cancer.

Umemura M, Nakakaji R, Ishikawa Y J Physiol Sci. 2023; 73(1):21.

PMID: 37759164 PMC: 10717067. DOI: 10.1186/s12576-023-00878-0.


Rhabdoid melanoma in a harpy eagle ().

Pinzon-Osorio C, Avila-Coy J, Gomez A, Marcela Alvarez-Mira D Vet Anim Sci. 2021; 13:100184.

PMID: 34189340 PMC: 8217705. DOI: 10.1016/j.vas.2021.100184.


Costunolide suppresses melanoma growth via the AKT/mTOR pathway and .

Huang H, Yi J, Park S, Zhang H, Kim E, Park S Am J Cancer Res. 2021; 11(4):1410-1427.

PMID: 33948365 PMC: 8085867.


AKT1 Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis.

Kircher D, Trombetti K, Silvis M, Parkman G, Fischer G, Angel S Mol Cancer Res. 2019; 17(9):1787-1800.

PMID: 31138602 PMC: 6726552. DOI: 10.1158/1541-7786.MCR-18-1372.


Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapy.

Dantonio P, Klein M, Freire M, Araujo C, Chiacetti A, Correa R Biosci Rep. 2018; 38(5).

PMID: 30166456 PMC: 6167501. DOI: 10.1042/BSR20180511.


References
1.
Staal S . Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci U S A. 1987; 84(14):5034-7. PMC: 305241. DOI: 10.1073/pnas.84.14.5034. View

2.
Kim M, Jeong E, Yoo N, Lee S . Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer. 2008; 98(9):1533-5. PMC: 2391109. DOI: 10.1038/sj.bjc.6604212. View

3.
Yin Y, Shen W . PTEN: a new guardian of the genome. Oncogene. 2008; 27(41):5443-53. DOI: 10.1038/onc.2008.241. View

4.
Stewart A, Mhashilkar A, Yang X, Ekmekcioglu S, Saito Y, Sieger K . PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells. Mol Med. 2002; 8(8):451-61. PMC: 2040008. View

5.
Huang J, Manning B . A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans. 2009; 37(Pt 1):217-22. PMC: 2778026. DOI: 10.1042/BST0370217. View